Imaging study to see how the imaging agent distributes in metastatic clear cell RCC

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early phase1 imaging study will evaluate the feasibility, biodistribution, and dosimetry of the imaging agent RYZ512 in adults with metastatic clear cell RCC. Participants will receive the imaging agent and undergo imaging procedures to characterize how it distributes in the body and the radiation dose delivered. The study seeks to determine whether the agent can be safely used for imaging in this cancer type and to inform future dosing and timing. No efficacy outcomes are the primary focus; safety, distribution patterns, and dosimetry are the key endpoints.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least 18 years old at the time of signing the informed consent form (ICF).
* Biopsy proven metastatic clear cell renal cell carcinoma (RCC)

Exclusion Criteria:

* Subjects taking below mentioned medications that cannot be stopped 5 half-lives prior to RYZ512 administration and cannot be restarted until all study-related imaging is completed: Anticonvulsants, Antipsychotics, Carbonic Anhydrase inhibitors, COX-2 Inhibitors, Sulfatase Inhibitors, Sulfonamides
* Women of Childbearing Potential that are pregnant or breastfeeding.

Note: Additional criteria may apply and will be assessed by the study site

Where it's running

• Research Facility
  Saint Leonards, New South Wales, Australia Recruiting
• Research Facility
  Nedlands, Australia Recruiting
• Research Facility
  Perth, Australia Recruiting
• Research Facility
  Christchurch, New Zealand Recruiting
• Research Facility
  Johannesburg, South Africa Active not recruiting
• Research Facility
  Pretoria, South Africa Active not recruiting

Study contacts

• Study coordinator: RayzeBio Clinical Trials
• Email: clinicaltrials@rayzebio.com
• Phone: (619) 657-0057

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Casdatifan for refractory metastatic clear cell kidney cancer

  This pilot, first-in-human study tests whether taking casdatifan by mouth can help people with metastatic clear cell renal cell carcinoma that has not responded to prior therapies.

  Recruiting Phase 1 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07748988

• CD70-Targeted Imaging-Guided Pause of Therapy in Metastatic Clear Cell RCC

  This study tests whether patients with metastatic clear cell RCC who respond to first-line PD-1/PD-L1 inhibitors plus VEGFR-TKI can safely pause treatment guided by CD70-targeted Immuno-PET/CT imaging.

  Recruiting at 5 sites Phase 2 Jinling Hospital, China · Nanjing, Jiangsu and 4 other locations · NCT07615348

• VSV-IFNβ-NIS plus ipilimumab and nivolumab for advanced or metastatic clear cell renal cell carcinoma

  This trial adds a virus-based therapy (VSV-IFNβ-NIS) to standard immunotherapy (ipilimumab and nivolumab) to see if it helps people with advanced or metastatic clear cell renal cell cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07510334

• Adding a probiotic to standard immunotherapy for advanced kidney cancer

  This trial tests whether adding MO-03 probiotic to standard immunotherapy helps people with advanced or metastatic clear cell kidney cancer.

  Recruiting at 41 sites Phase 3 SWOG Cancer Research Network · Fayetteville, Arkansas and 40 other locations · NCT07383441

• Nivolumab and ipilimumab with or without EXL01 for advanced or metastatic clear-cell and sarcomatoid renal cell carcinoma

  This trial tests whether adding EXL01, a live Faecalibacterium prausnitzii product, to nivolumab and ipilimumab helps adults with advanced or metastatic clear-cell or sarcomatoid renal cell cancer.

  Recruiting at 2 sites Phase 1 City of Hope Medical Center · Duarte, California and 1 other locations · NCT07128680

• Casdatifan plus cabozantinib versus placebo plus cabozantinib for advanced clear cell kidney cancer

  This trial tests whether adding casdatifan to cabozantinib helps adults with advanced or metastatic clear cell kidney cancer who progressed after PD‑1 or PD‑L1 immunotherapy.

  Recruiting at 191 sites Phase 3 Arcus Biosciences, Inc. · Gilbert, Arizona and 190 other locations · NCT07011719

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.